Navigation Links
MarketsandMarkets: Chronic Lymphocytic Leukemia Therapeutics Market Worth $2.2 Billion by 2020
Date:12/8/2011

DALLAS, December 8, 2011 /PRNewswire/ --

The report "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)" analyzes and studies the major market drivers, restraints, and opportunities in geographies such as North America, Europe, and Japan.

Browse market data tables and in-depth TOC on  "Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)".
http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-therapeutics-market-519.html


Early buyers will receive 10% customization on reports.

Chronic lymphocytic leukemia is also known as chronic lymphoid leukemia. It can be described as a slow increase in the number of white blood cells in the blood and the bone marrow. White blood cells guard the body from infections caused by bacteria. Chronic lymphocytic leukemia is divided by the type of lymphocyte involved, such as B-cell or T-cell. Chronic lymphocytic leukemia (CLL) accounts for 35% of the total leukemia.

The chronic lymphocytic leukemia therapeutics market in G8 countries was valued at $437 million in 2010 and is expected to grow at a CAGR of 13.43% from 2015 to 2020. Campath accounted for the largest share; i.e. 42.32% of the chronic lymphocytic leukemia therapeutics market [ http://www.marketsandmarkets.com/Market-Reports/chronic-lymphocytic-leukemia-therapeutics-market-519.html ] in G8 countries in 2010. However, in 2020, the market is expected to be dominated by Arzerra drug and GA101/RG7159 molecule, with sales amounting to $603 million and $994 million respectively.

According to WHO, chronic lymphocytic leukemia is expected to be more prominent in the developed world such as North America and Europe due to genetic factors. The other causes such as environmental factors and radiation exposure are also the causative of chronic lymphocytic leukemia. Global incidence of chronic lymphocytic leukemia was 94,960 in 2008 with the developing countries. Total 123,379 new cases were recorded in 2010 with 199,472 and 282,683 as the predicted new cases for 2015 and 2020.

The U.S. dominates the leukemia drug market in North America with 90.19% share; whereas Germany dominates the market of Europe with 20.49% share.

The major players in the market include F. Hoffmann-La Roche Ltd (Switzerland), GlaxoSmithKline Pharmaceuticals Limited (U.K.), Biogen Idec (U.S.), Celgene Corporation (U.S.), Genmab A/S (Denmark), Cephalon Inc. (U.S.), Genentech Inc. (U.S.) and Genzyme Corporation (U.S.).

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, energy and power, food and beverages, industrial automation, medical, pharmaceuticals [ http://www.marketsandmarkets.com/pharmaceutical-market-research-3.html ], semiconductor and electronics, and telecommunications and IT.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository. To know more about us and our reports, please visit our website http://www.marketsandmarkets.com.

Contact:
Mr. Rohan
7557 Rambler Road,
Suite 727, Dallas, TX 75231
Tel: +1-888-6006-441
Email: sales@marketsandmarkets.com
MarketsandMarkets Blog @ http://www.marketsandmarketsblog.com/
http://www.sandlerresearch.org/
http://twitter.com/marketsmarkets



'/>"/>
SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
2. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
3. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
4. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
5. MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015
6. MarketsandMarkets: Global Bioinformatics Market Worth $8.3 billion by 2014
7. MarketsandMarkets: Global Oncology Biomarkers Market Worth US$9.5 Billion by 2014
8. MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014
9. Marketsandmarkets: Global Minimally Invasive/ Non Invasive Market Worth $24.4 Billion by 2014
10. MarketsandMarkets: Global Biosimilars Product Market Worth $19.4 Billion by 2014
11. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Francisco, CA (PRWEB) , ... February 20, 2017 ... ... reduce infections in patients with catheters associated with peritoneal dialysis, announced today that ... light-based peritoneal dialysis catheter connection system in Peritoneal Dialysis International (PDI), the ...
(Date:2/19/2017)... ... February 19, 2017 , ... Expanding Portfolio to Include ... weighing equipment with the goal of expanding the reach of its quality and ... Starter water analysis meters were introduced into the market in 2014. , The ...
(Date:2/18/2017)... Research and Markets has announced the addition of the ... ... provides separate comprehensive analytics for the US, Japan ... estimates and forecasts are provided for the period 2015 through 2022. ... data and analytics are derived from primary and secondary research. This ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... flying hobbyists, and DJI, the world’s leading maker of unmanned aircraft systems (UAS), ... public safety officers to use drones effectively, and support educational outreach efforts. , ...
Breaking Biology Technology:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017  EyeLock LLC, a market leader of iris-based ... " What You Should Know About Biometrics in the ... authenticity is a growing concern. In traditional schemes, cryptography ... traditional authentication schemes such as username/password suffer from inherent ... offers an elegant solution to the problem of high-security ...
Breaking Biology News(10 mins):